Navigation Links
US Drugmaker Slapped Huge Fine for Misleading Doctors Over Addictive Painkiller

After four years of unrelenting pursuit by the Food and Drug Administration, the Purdue pharma of the US gave in, admitting it had made false claims about their popular painkiller Oxycontin.

They have agreed to pay up $634.5 millions for making false claims about the drug to boost sales and also pleaded guilty to charges of playing down Oxycontins addictive and euphoric properties.

Purdue pleaded guilty to a felony count of misbranding a drug with intent to defraud and mislead.

Under the agreement, it will pay a $600 million settlement, including a criminal fine, restitution to government agencies, and more than $276 million in forfeiture. In a separate civil settlement, Purdue will pay $100.6 million.

According to an investigation by the Food and Drug Administration (FDA)s Office of Criminal Investigations (OCI), the drug company trained its sales force to represent OxyContin as a drug that did not cause euphoria and was less addictive than immediate-release opiates; and allowed healthcare providers to have the mistaken notion that OxyContin was less addictive than morphine.

Over the last few years there have been instances of hundreds of overdose deaths linked to OxyContin's main ingredient oxycodone. The drug was marketed as a miracle pain reliever; less addictive and less subject to abuse than similar medications. However, it was later found that its contents could be highly addictive and even fatal.

Purdue Pharma also made false representations about the difficulty of extracting oxycodone, the active ingredient, from the OxyContin tablet, and labeled the drug as providing fewer peaks and valleys than with immediate-release oxycodone, the OCI said.

U.S. Attorney John Brownlee said, "With its OxyContin, Purdue unleashed a highly abusable, addictive, and potentially dangerous drug on an unsuspecting and unknowing public."

"For these misrepresentations and crimes, Purdue a
'"/>




Page: 1 2

Related medicine news :

1. Misleading anti-malarial drug
2. Misleading Advertisements for Prescription Drugs
3. The Effects Of Smoking Misleading
4. Lifting The Screen off Misleading Sunscreen labels
5. Misleading Health Claims On Food Labels No Longer Allowed in EU
6. Walkers Crisps Advertisements make Misleading Claims about Salt Content
7. Medical Council Of India Draws Public Attention on Misleading Ads.
8. Obesity Drug Advertisements Misleading Teens
9. Labeling of Dairy Products with Trans fat labels, Misleading to Consumers
10. WHO Condemns Tobacco Industry for Misleading Public
11. Cancer Doctors Okays Controversial Prostate Therapy
Post Your Comments:
(Date:10/13/2008)...ER WITH THE VIPER RESPONDER LE SPECIAL ...VISTA, Calif., Oct. 13 /PRNewswire-FirstCall/ -- D...DEI Holdings Inc. (Nasdaq: DEIX ), has joined,the... of Responder LE,Special Edition 2-Way Vehicle Sec...g Susan G. Komen for the Cure. For each pink Respo...
(Date:10/13/2008)...han Alzheimer,s patients, healthy controls , ...nson,s disease patients are more likely than healt...D deficiency, say researchers from the Emory Unive...pared vitamin D levels in 100 Parkinson,s patients...atched for age and other factors. , "Significan...
(Date:10/13/2008)...IH funding advances study Study needed becau...LIS, Oct. 13 /PRNewswire/ -- Advanced Circulatory ... ) announced today that it has received,an additio...itutes of,Health (NIH) to continue a study testing...rience cardiac arrest outside a hospital. Parts of...
(Date:10/13/2008)...re/ -- The National Coalition for,Quality Colorect...rns over,the National CT Colonography Study publis...icine. The evidence must be closely evaluated, and...s not without significant,potential risks. The Nat...remains the "Gold Standard" for colorectal cancer ...
Breaking Medicine News(10 mins):Health News:Supporting Susan G. Komen for the Cure(R) During National Breast Cancer Awareness Month 2Health News:Supporting Susan G. Komen for the Cure(R) During National Breast Cancer Awareness Month 3Health News:Parkinson's Patients More Prone to Vitamin D Deficiency 2Health News:3 Michigan Counties Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3
...or for cardiovascular diseases.A potbelly indicate...f the rest of the body is skinny as a beanpole. T...isk is the relationship of waist size to the hips,...icts an increased risk of heart attack. The study ...
...immings of cloned pig’s bacon, a jar of cloned cow...er; ‘Frankenstein foods’, as some// refer to it. ...stration (FDA) of US is getting ready to pass a bi...animal products. “We based our decision on lookin...
...'s 2002 Gay Pride, San Francisco Department of Pub...arize syphilis testing. In the above said campaig...roduced to Gayville, encouraging the many hundreds...hered there to get themselves tested for the big-S...
... a weight reduction pill, which works better and f... risk of heart disease, diabetes and cancer. Exis...ve to 10 percent when taken for a year. But men a...e new pill developed by Californian biopharmaceuti...
Other Medicine News:Health News:Pot Belly Is A Better Risk Predictor Of Heart Attack Than BMI 2Health News:Clones On the Menu 2
(Date:10/10/2008)...INGTON and MENLO PARK, Calif., Oct. 10 /PRNewswire...announced that it plans to present,long-term follo...rials next,week at the Cardiovascular Research Fou...diovascular Therapeutics (TCT) meeting in Washingt... studies designed to investigate,the safety and ef...
(Date:10/10/2008)...SANTON, Calif., Oct. 10 /- TriReme Me...authorized to affix the CE (Conformite,Europeenne)...M) Coronary,Stent System, a unique main vessel ste...ronary bifurcations., Representing the next gener...tem has potential use in a quarter of the 2.2 mill...
(Date:10/9/2008)...pps Translational Science Institute, Navigenics, A...lth study, SAN DIEGO, Oct. 9 /- A co...eaders have joined forces in a first-of-its-kind,r...ersonal genetic testing,on people who choose to re...risk for developing certain diseases., Sponsored ...
(Date:10/8/2008)...ona Heart Institute Pioneers Research That May Off...ct. 8 /- Nationally, over 3,000 peopl...ease on life. Sadly, only half,of those will recei...na,Heart Institute (AHI) is paving the way for how..., To view the Multimedia News Release, go to:, ht...
Breaking Medicine Technology:XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week 2TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 4Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 5Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Patient Safety Technologies Closes on 242 325 Million in Equity Financing 25845 1Patient Safety Technologies Closes on 242 325 Million in Equity Financing 25845 2Replidyne Announces Restructuring of Operations 25843 1Replidyne Announces Restructuring of Operations 25843 2VaxGen Provides Financial Update Following the Filing of Its 10 Q for Second Quarter With SEC 3B Results Include 248 5 Million Charge in Respect of M 25840 1VaxGen Provides Financial Update Following the Filing of Its 10 Q for Second Quarter With SEC 3B Results Include 248 5 Million Charge in Respect of M 25840 2VaxGen Provides Financial Update Following the Filing of Its 10 Q for Second Quarter With SEC 3B Results Include 248 5 Million Charge in Respect of M 25840 3New England Journal of Medicine Publishes Phase III Results of VELCADE 28R 29 28Bortezomib 29 for Injection in Previously Untreated Multiple Myeloma 2902 1New England Journal of Medicine Publishes Phase III Results of VELCADE 28R 29 28Bortezomib 29 for Injection in Previously Untreated Multiple Myeloma 2902 2New England Journal of Medicine Publishes Phase III Results of VELCADE 28R 29 28Bortezomib 29 for Injection in Previously Untreated Multiple Myeloma 2902 3New England Journal of Medicine Publishes Phase III Results of VELCADE 28R 29 28Bortezomib 29 for Injection in Previously Untreated Multiple Myeloma 2902 4New England Journal of Medicine Publishes Phase III Results of VELCADE 28R 29 28Bortezomib 29 for Injection in Previously Untreated Multiple Myeloma 2902 5New England Journal of Medicine Publishes Phase III Results of VELCADE 28R 29 28Bortezomib 29 for Injection in Previously Untreated Multiple Myeloma 2902 6
...23, 2007 /PRNewswire-FirstCall/ -- Shire plc,annou...l system),the first and only non-oral medication ...ctivity Disorder (ADHD) in children aged 6,to 12 y...control,and tolerability, according to results of ...can Psychiatric Association (APA),annual meeting i...
...--(BUSINESS WIRE)--May 23, 2007 - Synta,Pharmaceut...mpany,focused on discovering, developing, and comm...edical conditions, today announced,that survival a...trial in metastatic melanoma of the Company,s lead...ted at the annual meeting of the,American Society ...
Other Medicine Technology:12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 312-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 412-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 512-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 612-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 712-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 812-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 9Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 2Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 3
The VISUCAM non-mydriatic fundus camera increases the quality and simplicity of fundus imaging. Compact, yet big enough to set the standard in ophthalmic photography, it features a unique combination
The Afinion HbA1c test and the fully automated Afinion Analyzer, give you reliable facts conveniently available when and where you need them. Advising the patient can be carried out with confidence.
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket.
The ARK-730A initiates automatic measurement at the optimum measurement point. The ARK-730A maintains fogging throughout multiple measurements, saving total examination time.
Medicine Products: